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A R T I C L E  I N F O A B S T R A C T
Article type:Original article Objective(s): CD19 is a transmembrane glycoprotein of immunoglobulin superfamily. In order to treat lymphoma, monoclonal antibodies (mAb) can target different antigens, including CD19, CD20 and 
CD22 on the surface of B-cells. Along with biotechnology progress, a new generation of antibodies 
is introduced, with the purpose of eliminating the defects of the previous generation. Among the 
most developed one are nanobodies (Nb).  Nbs are a unique kind of camelid single domain antibody 
fragments with a broad range of medical applications. Unique physicochemical properties of Nbs have made them ideal candidates for therapeutic and diagnostic applications. 
Materials and Methods: An immune gene library was created, and several CD19 specific Nbs were 
selected through antigen panning process, and their molecular properties as well as specificity, 
sensitivity, affinity and immunoreactivity against CD19 positive and negative cells were evaluated. 
Results: The Nb library was prepared with 7.2 x107 members. We managed to isolate a panel of CD19-
specific Nbs after the last round of selection with the affinity of isolated Nbs being estimated at the 
standard range of 15-35 nM.  Sequence analysis of positive clones was indicative of the fact that 12 
variable sequences were confirmed. Of all these 12 clones, 2 clones with the greatest level signal in 
ELISA underwent subsequent analysis. Our sequencing results indicated high sequence homology 
(approximately 90%) between the Nb and Homa variable immunoglobulin domains.
Conclusion: Specific Nbs possess the potential to be used as novel therapeutic approaches in order to treat autoimmune diseases and B-cell lymphoma.
Article history:Received: Oct 9, 2017Accepted: Sep 28, 2017
Keywords: 
CD19Drug delivery systemLymphoma
NanobodyPhage display
►Please cite this article as:  
Banihashemi SR, Zavaran Hosseini A, Rahbarizadeh F, Ahmadvand D. Development of specific nanobodies (VHH) for CD19 immuno-targeting of human 
B-lymphocytes. Iran J Basic Med Sci 2018; 21:455-464. doi: 10.22038/IJBMS.2018.26778.6557
Introduction
CD19 is a transmembrane glycoprotein of the 
immunoglobulin superfamily (IgSF) (1). CD19 is 
expressed by both normal and malignant B-cells as well as dendritic cells, and it is an important and effective 
biomarker (2). The study of knockout and transgenic 
mouse models of CD19 shows that CD19 plays a critical 
role in maintaining the balance between antigen-induced and humoral responses, and reveals induced 
tolerance (3). For the treatment of lymphoma, different 
monoclonal antibodies (mAb) have been utilized that are selective for various antigen on the outer surface 
of B cells (4). Among those, Rituximab can target the 
CD20 on the outer layer of B-cells and it is one of mAbs 
that has revolutionized the treatment of lymphoma (5). 
However, due to the lack of expression of CD20 on the surface of B-cell lineage including plasma cells, there 
is an urgent need for an alternative antigen target (6). 
CD19 is one of the proposed alternatives for CD20 
(7). Due to the expression of CD19 on B-cells lineages, many studies have recently focused on this antigen as a 
cancer-specific biomarker (8). Hence, several research 
centers have put significant effort and investment 
on designing and producing a novel mAb, which can 
be used against CD19 antigen (9). These efforts are 
focused on developing therapeutic targets against B-cell 
malignancies. Malignancies that are caused by lack of B- 
cell efficiency are very wide ranging and dangerous(10). 
Successful preclinical research has paved the way for 
the clinical trials, mainly based on the first generation 
of immunoconjugated mouse anti-CD19 toxin, but due to poor biochemical reactants and human anti-murine 
antibody (HAMA) generation most of these trials 
ended up in failure (11). These problems have had a 
considerable limiting influence on the clinical practice, 
culminating in the emergence and production of a new generation of antibodies. Based on the novel structure and functional properties of naturally–occurring heavy 
chain-only antibodies (12), derived nanobodies (Nbs) 
are a unique kind of camelid single domain antibody 
fragments with a broad range of medical applications 
(13). The heavy chain antibodies of camel were first 
discussed by Ungar-Waroni et al. who demonstrated 
many Ig-Like proteins in dromedary serum and proved 
their significance in the process of passive immunity 
transmission from dam to calf through colostrum (14). Heavy chain antibodies include an antigen-binding 
region, VHH and two constant domains. Sufficient 
data is available on genetic elements of Nbs, yet in vivo production process of these molecules is still ambiguous. 
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Until this moment, only three secondary functional IgGm 
serum of Camelidae have been identified: IgG1 can be 
defined as a heterodimer, which consists of homodimers 
with heavy and light chains. On the other hand, IgG2 and IgG3 consist of merely heavy chains. As a result, they may 
be considered as famous heavy chain antibodies (hcAbs) 
(14,15). The Nbs resistance to severe conditions makes them suitable entities for administration via different 
routes (topical, oral or respiratory)(16). Besides genetic map of the single variable domain 
VHH that binds to antigen, in order to produce Nbs with 
high affinity, among isolated B-cells, activated clones 
against the target antigen (CD19) must be identified 
following immunization of a camel (17). A common method to achieve this goal is via phage display through 
which the antigen is expressed on the phage surface 
in vitro and then the favorable clone is isolated by 
consecutive panning (18).The present research has sought to create an immune gene library from camel and to select and validate the 
specific Nbs against CD19 on human B-cells with the aid of phage display technology.
Materials and Methods
Antigens and antibodies
Recombinant human CD19 protein was purchased 
from Abcam (Cambridge, UK). The anti-M13 horseradish 
peroxidase (HRP) conjugated antibody and HRP-linked 
anti-mouse IgG produced in goat were provided from 
Sigma-Aldrich (St Louis, MO, USA). The mouse HRP and 
fluorescein isothiocyanate (FITC)-linked monoclonal 
anti-His tag antibodies were obtained from Abcam 
(Cambridge, MA). The Human CD19 mAb conjugated to 
PE was purchased from Abcam (Cambridge, MA). Finally, 
the pCom3XSS vector was purchased from Addgene 
(Cambridge, MA).
Bacterial strains and culture media
Escherichia coli (E. coli) XL1-Blue (Merck, Germany) 
was considered appropriate for the purpose of phage 
display design and it was cultivated in Luria– Bertani 
(LB) and 2XYT growth mediums, supplemented with 100 µg/ml ampicillin. E. coli TAP10F (Thermo Fisher,USA) 
was utilized for Nb expression. TAP10F was grown in SB 
medium, supplemented with 100 µg/ml ampicillin and 
50 mM MgCl2 (19).
Cell lines and conditions of cultivation
B cell lines Raji, Ramos, Namalwa and Daudi (CD19 
Positive) and K506 (CD19 Negative) were purchased 
from the national cell bank of Iran (Pasture Institute of 
Iran, Tehran, Iran) and cultured in RPMI 1640 (Gibco, 
USA), supplemented with 10 % (v/v) heat-inactivated 
fetal bovine serum, 2 mM L-glutamine, 0.4 mM sodium pyruvate, 100 U/ml penicillin, and 100 µg/ml 
streptomycin (Gibco, Scotland, UK). Respective cell lines 
were cultured in similar conditions (80% humidity, 5% 
CO2 at 37 °C)(19).
VHH amplification and library construction
Two relatively young female camels were given six 
intramuscular and intradermal Namalwa injections 
every three weeks. About 106 cells/ml supplemented 
with 2 ml Freunds complete adjuvant were utilized for 
the ﬁrst injection. Booster immunization was performed using 106 Namalwa cells/ml along with Freund 
incomplete adjuvant. The last injection was performed 
with 106 Namalwa cells/ml and no adjuvant. Eight days 
following the sixth injection, a blood sample (about 250 
ml) of the subjects was obtained from the immunized 
camels and the peripheral blood lymphocytes were 
isolated by centrifugation on a Ficoll (Sigma-Aldrich) 
discontinuous gradient. Total RNA was extracted from 
the peripheral blood lymphocytes (Nucleo Spin RNA 
II, Qiagen, USA) and first strand cDNA was synthesized 
from total or polyA+RNA, using Prime Script RTase, 
a M-MLV (Moloney Murine Leukemia Virus)-derived 
reverse transcriptase (TAKARA, Japan). Then, the gene 
fragments encoding Nbs were ampliﬁed by nested PCR. 
In order to amplify VHH, a nested PCR was designed. 
The first PCR sought to amplify the fragments between 
framework 1 and regions correlating to CH2, using 
five sets of specific primers including CALL001: 5’-
GTC CTG GCT CTC TTC TAC AAG G-3’; CALL002: 5’-GGT 
ACG TGC TGT TGA ACT GTT CC-3’; VHBACKA6: 5’- GAT 
GTG CAG CTG CAG GCG TCT GG(A/G) GGA GG-3’; and 
CH2FORTA4: 5’-CGC CAT CAA GGT ACC AGT TGA-3’. 
Fragments (600 and 700 bp) driven from heavy chain 
antibodies were extracted from agarose gel using a 
kit designed for gel purification (Invitrogen, USA). 
They were subsequently utilized as templates for the 
second round of PCR. VHH was amplified using four 
specific degenerated VHH primers including VHH-F: 
5’- CTGGCCCAGGCGGCCGAGGTGCAGCTG(C/G) (A/T) 
G(C/G) A (G/T) TC (G/T) G-3’; and VHH-R primer: 
5’-ACTGGCCGGCCTGGCCTGAGGAGACGGTGATGACC 
(A/T) GGGTC-3’. These primers were bound to regions 
corresponding to framework 1 and framework 4. VHH 
fragments were purified from agarose gel and cloned into a sfiI digested pComb3xSS phagemid vector. 
Ampliﬁed Nb products were digested with sfiI (Thermo 
Scientific, USA) and the resulting fragments were 
ligated into phagemid vector pComb3x SS. The ligation 
compound was transformed into E. coli XL1-Blue via 
electroporation (2500 v, 5 msec in a 0.2 mm covet) 
and put on LB plates, which contained ampicillin. This 
library (Nb repertoire) was expressed on phages after 
infection with 1012 to 1013 plaque/ml M13KO7 helper 
phage (Thermo Scientific-USA) and the phages were 
isolated through precipitation using PEG 8000 to 4% 
w/v and 6 g of sodium chloride to 3% w/v (19-21). 
Selection of the CD19 binding nanobodies via antigen 
panning 
Biopanning was used to isolate favorable clones in 
the library. In this regard, a 6-wells plate was coated 
with the CD19 antigen (25 ng/well) or bovine serum 
albumin (BSA; 500 ng/ml, for subtractive panning) in a 
temperature of 4 °C overnight. Binding of respective Nb-
carrying phages to the coated wells was accomplished 
through five rounds of panning. The wells were rinsed 
twice using phosphate buffered saline (PBS) and then 
blocked by PBS containing 2 % (w/v) ELISA-grade BSA 
and 1 % (w/v) skimmed milk at 37 °C for 2 hr. The phage 
particles (about 3 ×1012 transducing units) aspirated 
with the blocking solution in a total volume of 2 ml 
of PBS with 4 % BSA and pre-incubated on the BSA-
coated wells at 37°C for 2 hr (to aspirate non-speciﬁc 
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binders) and then transferred to the CD19-coated wells. 
After incubation at 37°C for 3 hr, the supernatants were 
aspirated and the wells were washed four times with 0.5 
% Tween 20 in PBS (PBST) and twice with PBS alone. 
After shaking out of the final washing solution, 500 µl 
of freshly prepared 1 mg/ml trypsin in TBS was added 
to every single well.  For the next rounds of panning, the 
eluted phages were ampliﬁed by infecting log-phase 
E. coli XL1-Blue cells followed by their super-infection 
with the helper phage, as detailed above. In addition, 
input and output phages were titrated by infecting the 
log-phase XL1-Blue competent cells using an aliquot 
of phage particles and then the samples were plated 
out on LB-ampicillin plate. Five consequent rounds of 
panning were carried out and the intensity of selection 
was increased with each phase using increasing Tween 
concentrations (0.5–10%) in the washing step (19, 20, 
22, 23).
Polyclonal phage ELISAThe improvement of the selection process can be accomplished through different methods such as polyclonal phage ELISA. Polyclonal phage ELISA and 
polyclonal phage cell ELISA wherein the phage pools 
are produced at the end of each stage of panning were 
examined with phages from the unplanned library. In 
polyclonal phage ELISA, CD19 antigen (20 ng/well) 
and BSA (500 ng/ml), as negative control in PBS (pH 
7.2), were used to coat the wells of microtiter plate and 
incubated overnight at 4 °C. After rinsing with PBS twice, 
the wells were blocked with 1% skimmed milk and 2% 
BSA/PBS for 2 hr at 37 °C. Then, the blocking buffer was aspirated and 1012 transducing units of antigen panning 
output phages were added and incubated for 4 hr at 
37 °C. After five rounds of washing steps using PBST, 100 
µl of the anti-M13 antibody conjugated to HRP (1/1000) 
were supplemented and incubated for 4 hr at 37 °C. 
Subsequently, the plate was rinsed five times using PBST 
and PBS and the peroxidase enzyme activity was detected 
by adding 70 µl of 3, 3´, 5, 5´-tetramethylbenzidine 
(TMB) as substrate. The reaction was blocked by the addition of 50 µl of 1 M H2SO4 to the confluent cells in 
96-well cell culture plates. In an attempt to preserve the 
original structure of the CD19 antigen on the Namalwa 
cells and to prevent the cell lysis, all the procedures were 
conducted at 4 °C. Subsequently, the wells were depleted 
and pre-incubated with 3% BSA/PBS on ice for 30 min, 
in order to eliminate non-speciﬁc binding, followed 
by 1 hr incubation with 1012 transducing units of cell-panning output phages on ice. After the incubation time, 
the wells were washed with 1% BSA/PBS and the assay 
was operated as explained previously (20, 21).
Selection of CD19-specific phage nanobodies and DNA 
sequencing
The antigen-specific phage clones were recognized by monoclonal phage ELISA using the anti-M13 mAb. As many as 800 randomly nominated single clones 
were selected from output phages and the antigen was 
analyzed using ELISA and PCR, for their binding capacity 
to the CD19, in order to detect the VHH sequence as 
discussed previously. The clones were dimmed positive 
when the optical density (OD) of 450 nm, measured for 
CD19-coated wells was around three times of baseline 
of BSA-coated wells. The clones with positive phage 
were isolated, characterized and sequenced to identify 
the novel Nb. An algorithm was utilized to produce a 
tree from given distances (or dissimilarities) between 
sequences (Neighbour-joining phylogenetic options and 
distance Gishin model)(24-26). 
Production of soluble nanobodies
In order to produce soluble Nbs, phages picked in 
monoclonal phage ELISA were utilized for infection of 
non-suppressive strain TAP10F. Transformants were developed in 1 L SB containing 100 µg/ml ampicillin, 
while they were shaken at 250 rpm at 37 °C.The process 
of  protein expression was induced at OD 0.8 using 0.5 
mM isopropyl-b-D-thiogalactopyranoside (IPTG) and 
the culture was incubated for 24 hr in a temperature 
of 24 to 27 °C. After incubation, the bacterial pellet was resuspended in PBS, containing 1 mM of the protease 
inhibitor phenylmethylsulfonyl ﬂuoride (PMSF) and 
sonicated. The cell debris was centrifuged at 14,000 
rpm at 4 °C for 45 min in order to isolate the transparent 
and clear supernatant, which contains soluble Nbs that 
are expressed. The 6× His-tagged Nbs were puriﬁed by 
chromatography, utilizing Ni-NTA resin (Qiagen, USA). 
The elution was then rinsed using four sample volumes of PBS, containing protease inhibitor using a centriprep 
5 filtration system, which has an MW cut-off of 5 kDa. 
Protein concentration was measured using Bradford 
assay. Puriﬁed Nbs were used for further specification or stored in at -20 °C (19, 27, 28).
SDS-PAGE and Western blot analysis
In order to confirm the molecular weight of the 
soluble Nbs, expressed by the speciﬁc positive clones, 
protein samples were electrophoresed using a reducing 
sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) and transferred onto a nitrocellulose membrane by 
electroblotting. After the membrane was blocked with 
2% BSA in TBS for 2 hr at 37 °C, it was probed using HRP-conjugated anti-HA antibody, diluted in TBS containing 
0.1% BSA. The membranes were washed three times 
with TBS-T and twice with TBS and then visualized 
using 4-chloro-1-naftol substrate (29) . 
Analysis of the soluble nanobody reactivity towards 
the puriﬁed CD19
Each selected Nb (2 µg/ml) was incubated in triplicate 
at 37 °C for 1 hr in a microtiter plate coated with the 
CD19 antigen and BSA (as negative control) and blocked 
with 1% BSA and 3% skimmed milk. Having rinsed it three times using TBS-T, 100 µl anti-HA antibody 
conjugated to HRP (diluted 1/10000 in TBS containing 
0.1% BSA) was supplemented and the resulting mixture 
was incubated at 37 °C for 2 hr. After washing with TBS-T 
and TBS, TMB substrate was added, the color of the 
reaction was detected and the absorbance intensity was 
measured at 450 nm (30).
Analysis of binding speciﬁcity
The individual Nbs were tested to measure 
their specificity and possible cross-reactivity with structurally relative compounds such as casein, porcine 
submaxillary mucin (PSM), skimmed milk, BSA, HER2, 
VHH and Endoline. Several types of antigens were 
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coated in microtiter plates (1 µg/ml) and tested with 
different concentrations of anti-CD19 Nb (31).
Analysis of binding sensitivity
In an attempt to come up with more detailed 
characterization of the selected Nb fragments, ELISA 
was conducted by reducing the amount of the coated 
CD19 antigen. A range of antigen concentrations (0, 
6.25, 12.5, 25 and 50 ng/ml) was prepared in PBS 
buffer and coated in microtiter plates at 4 °C overnight. 
Subsequently, different soluble Nbs (2 µg/ml) were 
added and the bound antibodies were determined using 
HRP-labeled anti-HA antibody(19, 32) .
Analysis of competitive binding
A competitive binding assay was carried out to assess 
binding of the nominated Nbs to the soluble antigen. All 
rounds of this test were carried out similar to the analysis 
of the soluble Nb reactivity, with the exception that the 
Nb solutions were pre-incubated with serial dilutions of 
soluble CD19 antigen (up to 20 ng/ml) for 2 hr before 
they were added to the wells. Bound antibodies were 
monitored by HRP-labeled anti-HA antibody (20).
Afﬁnity determination
The afﬁnity constant determination of the nominated 
Nbs was performed using the non-competitive enzyme immunoassay described by Beatty et al. The microtiter 
plates were coated using 100 µl of two different 
concentrations (10 and 100 ng/ml) of the CD19 antigen 
in BSA, and incubated at 4 °C for one night. The wells were 
blocked with 1% BSA in 250 µl TBS and then incubated 
with different concentrations of soluble Nbs (10–40 
nM) for 2 hr at 37°C. The bound Nbs were detected using HRP-conjugated anti-HA antibody and the signal 
intensities were measured at 450 nm. The affinity of the 
Nb was estimated at the concentration yielding half-
maximum binding to CD19 antigen(19, 33).
Analysis of nanobody reactivity by cell ELISA
Cell ELISA was designed to study the reactivity 
of single soluble Nbs as well as the Nb mixture with 
Namalwa and K506 cell lines. In this setting, the 3% BSA/PBS solution acted as a negative control. Both cell lines 
were developed up to level of confluency on 96-well cell 
culture plates. Soluble Nbs were then added to each well and processed as discussed above in polyclonal phage 
cell ELISA, with the exception of using anti-HA mAb 
instead of HRP linked to anti-M13 antibody (19, 20).
Flow cytometry studies
Fluorescence-activated cell sorting (FACS) experi-
ments were conducted to determine the binding of SRB-
37 and SRB-38 to K562, Raji, Ramos, Daudi and Namalwa 
cells. For this purpose, 1×106 cells in the exponential 
growth phase were seeded in sterile tubes. Cells were 
incubated with Nbs for 2 hr at 4 °C, and then they were 
rinsed using cold PBS. Binding of Nbs was analyzed in a 
Becton Dickinson FACScan (BD Biosciences, USA), after 
labeling with mouse anti-His mAb. The binding of Nbs 
to Raji, Ramos, Daudi, Namalwa and K562 cells was 
characterized by rightward shifts in the fluorescence 
peak. Commercial anti-CD19-PE (BD Biosciences, USA) 
were used to demonstrate the expression of CD19 on 
the cell lines (34).
Statistical analysis
Various experimental groups were compared against 
others using the Kruskal–Wallis test. The Mann–Whitney 
test was conducted to define the statistical significance 
of the differences between two various statuses. The 
software used for the statistical analysis was Stata 3 for 
windows. A P-value of less than <0.05 was considered 
to be statistically significant. The phylogenetic tree was 
produced using BLAST pairwise alignments, and Max 
sequence difference >0.5 for sequence grouping was considered accurate.
Results
Constriction and enrichment of the phage-displayed 
CD19 binding nanobodies 
Mononuclear cells were separated from heparinized 
blood of an immunized camel. Total RNA was extracted from 106 cells and reverse transcribed to cDNA, and 
subsequently used as the PCR template. The amplified 
fragments were extracted from classical antibody (900 
bp) and the CH2-located regions and framework 1 were 
amplified (heavy chain antibody) (600-700 bp) (Figure 
1a). In the second round of PCR, the VHH fragments 
(400 bp) were amplified with specific primers that 
bind to framework 1 and framework 4 and the variable 
region (Figure 1b). Sfi1-digested vector and VHH were 
ligated to form the final fragment (Figure 1c). Finally, 
the Nb library was prepared with as many as 7.2 x107 members.
Nb-expressing phages were obtained from the 
immune library following superinfection with M13KO7. 
In order to enrich speciﬁc Nbs against CD19, ﬁve 
rounds of biopanning were conducted on puriﬁed CD19 antigen.  Since enforcing more rounds of selection in 
panning leads to a remarkable decrease in specificity 
of the phages, panning was accomplished in five cycles. 
Titration of each stage showed a measured increase 
in the output/input ratio of phage particles following each round of panning, demonstrating the developing 
enrichment of the CD19-speciﬁc clones during the 
primary rounds of panning (Table 1). This ratio increased 
by 20 fold following the fifth biopanning round. Analysis 
 
  
Figure 1. library construction. (a) First PCR product analysis by agarose 
gel electrophoresis (1%). (b) Second PCR product analysis using gel 
electrophoresis (1%). VHH fragment with  400-500 bp size is marked
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of the speciﬁc binding of each output pooled phage with 
an anti-M13 antibody further verified the success of 
the selection process (Figure 2). The yield of the third, 
fourth, and fifth biopanning rounds was monitored by 
ELISA for exclusive CD19-speciﬁc binders. 
Of the total 800 randomly selected colonies, 12 
clones showed high-binding ability to the CD19 antigen 
with very low affinity against BSA. Sequence analysis 
of positive clones disclosed that 12 unique sequences 
were verified. Of these 12 clones, 2 clones (i.e., SRB37 
and SRB85) showing the highest signal in ELISA were 
subjected to subsequent analysis (Figure 3 a,b). The 
amino acid sequences of the two selected clones are 
confirmed in Table 2 and the algorithms showed a high 
similarity between human antibodies and SRB-85 and 
SRB-37 (Max sequence difference was 0.45) (Figure 3 c, 
d).
Production of soluble nanobodies
Generation of soluble Nbs was carried out after transformation of selected phagemids into E. coli 
TAP10f cells. The expressed proteins were extracted from IPTG-induced cultures of TAP10f by cell sonication 
and puriﬁed by chromatography. In order to support the 
suitable expression of Nb proteins and to characterize 
their molecular weight, equal amounts of each Nb 
samples were resolved by SDS-PAGE under reducing 
conditions, and then detected via western blotting. 
Both Nbs were monomeric with the molecular weight of 
around 14–16 kDa. The expression yield of Nbs varied 
from 1 to 5 mg/l of culture. But after extraction, Nb 
was in dimer form. To prevent dimerization, a standard 
amount of 2-ME was used (Figure 4). The soluble Nbs 
were analyzed by ELISA for their binding capacity to 
the CD19 antigen. Both selected Nbs were proven to be 
speciﬁc toward the target protein (CD19) (Figure 4a,b)
Speciﬁcity
In an attempt to confirm the speciﬁcity of the 
nominated Nbs, ELISA assay was conducted with 
serial dilutions of anti-CD19 Nbs. All individual Nbs 
and mixture of Nbs were highly specific for the CD19 
antigen, while the control Nb had no sign of binding 
to the target (Figure 5a,b,c,d). However, when single 
 Selection round Input Out put Ratio Out /In put Enrichment ratio First 1.7 × 10 12 1.2 ×10 7 7×10 -6 1 Second 1.4 × 10 12 1.6 ×10 7 1.1 ×10 -5 1.5 Third 1.9 × 10 12 7.4 ×10 7 3.8 ×10 -5 5.4 Forth 2.3 × 10 12 1.8 ×10 8 7.8 ×10 -5 11 Fifth 2.7 × 10 12 3.9 ×10 8 1.4×10-4 20 
 
  
Table 1. Titration results and enrichment of the CD19-specific phages 
follow biopanning of the nanobody gene library on purified antigen 
(antigen panning)
 
  
Figure 2. Phage ELISA: Results of anti-CD19 virions after biopanning 
of the nanobody gene library phages through five panning rounds 
(fourth and fifth rounds), that yielded the highest signals in ELISA 
(Kruskal–Wallis one-way analysis of variance, P=0.003) and were 
used for isolation of anti-CD19 nanobodies. The assay was performed in triplicate and the results are the average of three optical densities 
(at 450 nm) for each cell line±SD
 
Figure 3. Selection of CD19-specific phage nanobodies (A) clonal selection on the plate (B) clonal PCR and ELISA (C and D), Blast tree SRB-37 
and Blast tree SRB85, Neighbor-joining phylogenetic tree of the dromedary germline VH and VHH segments. Database sequences that differed 
by >7.5% in sequence relative to the mined germline sequences from the RM genome were considered to represent distinct genes. The neighbor 
joining method is a method for re-constructing phylogenetic trees, and computing the lengths of the branches of this tree. In each stage, the two 
nearest nodes of the tree (the term "nearest nodes" will be defined in the following paragraphs) are chosen and defined as neighbors in our tree). 
For purposes of this sequence tree presentation, an implicit alignment between the database sequences is constructed based upon the alignment 
of those (database) sequences to the query
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Nbs were incubated with the CD19 antigen, no cross-
reactivity was detected with other proteins.
Sensitivity
The binding sensitivity of anti-CD19 Nbs was 
examined by ELISA (Figure 6). Both selected Nbs 
 Clone FR1 CDR1 CDR2 FR2 SRB-85  EVQLLESGGGLVQPGGSLRSCEAS GFN----AMT SIDS-----WTDAVKG WVRQPPGKGLEWVS SRB-37  EVQLQESGGGLVQPGGSLRLSCAAS GF-----IYMV GIKTERDG------VKG WVRQAPGKGLEWLS Clone  FR3 CDR3 FR4 SRB-85  RFAISQDNAKNTVYLQMNSLKPEDTAMYYC AL-----SKCYT---RVYDY WGQGTQVTVSSG SRB-37  RFTIPRDNAKNTLYLQMNNLKSEDTALYYC ATE---E--ND WGQGTQVTVSSG 
 
 
  
Table 2. Sequence alignment of the selected anti-CD19 nanobodies with FR1-4 and CDR1-3 the framework regions (FRs) and complementarity 
determining regions (CDRs) are indicated
 
 Figure 4. SDS-PAGE and Western blotting analysis; (a) SDS-PAGE gel stained with Coomassie blue; lane marker: MW marker; lane 37 (clone 37) 
and 85 (clone 38): cell lysate containing expressed VHH following induction with 0.5 mM isopropyl-b-D-thiogalactopyranoside (IPTG); lane before 
IPTG: bacterial host before induction. (b) lane 1: MW marker; lane 2 and 3: VHH clones 37 and 85 expressed following induction with 0.5 mM IPTG, 
representing the specific reaction of the horseradish peroxidase (HRP)-conjugated anti-His Tag antibody with nanobodies, which both formed 
dimer (30kDa) in lanes 2, 3, 4, and 5; lane 6: marker; lane 7: VHH dimer was removed and monomer 15 kDa VHH was purified (4CN Staining)
 
  
Figure 5. Binding specificity of the anti-CD19 nanobodies. (a) Two selected nanobodies specifically recognized the target antigen and the control 
nanobody that showed no specificity for CD19 and did not bind to the target antigen. (b) Specific binding of the mixed nanobody (SRB-37 and 
85),(C) SRB-37 and (D) SRB-85 to CD19 and other antigens: bovine serum albumin (BSA), VHHr, PSA, porcine submaxillary mucin (PSM), casein, 
HER2, CD19 and skimmed milk is shown as control factor to confirm that the selected nanobodies were highly specific for the CD19 antigen. Each 
point is reprehensive of the average of three repetitions±SD
461Iran J Basic Med Sci, Vol. 21, No. 5, May 2018
Development of VHH for CD19 Banihashemi et al.
could quickly bind to the coated CD19 antigen at a 
concentration of 10 ng/well.
Competition assay
Incubation of the Nb solutions with gradually 
increasing amounts of the soluble CD19 antigen resulted 
in blockage of the binding to CD19-coated wells (Figure 
7). As depicted in figure 7, the binding blockage pattern 
of different Nbs differs between the two clones.
Afﬁnity
The binding afﬁnity of the isolated Nbs was specified 
by enzyme immunoassay, which demonstrated the 
analysis constants of Nb binders for CD19, arrayed from 
15 to 33 nM (Table 3). 
Cell ELISA
The Namalwa cell line that expresses the CD19 
protein was used to test the immunoreactivity of the 
selected Nbs against the native form of the antigen. A 
considerable OD discrepancy between the soluble Nbs 
and the negative control was indicative of the fact that 
these Nbs could find the native conformation of CD19 on 
the surface of the Namalwa cells (Figure 8). Furthermore, 
combined Nbs in a mixture proved to be more effective 
than the single Nbs in terms of detecting CD19 on the 
surface of the B- cells. However, no immunoreactivity 
was detected against the K562 cell line (CD19 negative 
cells).
Flow cytometry studies
Raji, Ramos, Namalwa and Daudi cell lines expressing 
the CD19 protein were utilized for flow cytometry assay 
to prove binding of the selected Nbs to this antigen. A 
considerable rightward shifts in the fluorescence peak 
of the Raji, Ramos, Namalwa, Daudi and the negative 
control K562 cell lines was observed (Figure 9). When 
combined SRB-37 and SRB-38 in a mixture were tested, 
the cocktail could effectively detect CD19 on the surface 
of the B-cells. However, no immunoreactivity was 
observed in the K562 cell line (CD19 negative cells). 
Anti-C19-PE antibody (Becton, Dickinson and Company 
USA) verified that all tested cell lines with the exception 
of K562,  as control negative, represent over 90 percent 
expression of the CD19 receptor on their surface.
DiscussionProduction of mAb is one of the most advanced 
technologies in the pharmaceutical industry (35). 
Monoclonal antibodies are now extensively used to treat various diseases such as immunological disorder and 
cancer (35). Antibody fragments are now at the focus of most researches since these small molecules have many 
advantages, and can be used for therapeutic purpose (36). 
In this study, we employed phage display technology to 
obtain anti-CD19 specific Nbs from a large one-humped 
camel derived immune Nb library (37).  Thus far, various reports have focused on selection of recombinant 
antibody fragments specific for CD19 antigen. A brief 
overview of anti-CD19 mAb can be found on the list such 
as Blinatumomab, Coltuximabravtansine, MOR208 and 
MEDI-551 (7). All of these antibodies are at different 
stages of the clinical trial or in the market, but most of 
 
  
Figure 6. Binding sensitivity of selected nanobodies; The CD19 
antigen was coated at different concentrations (0, 10.20, 40, 80, 
160, 320, and 640 ng/well); subsequently, SRB-37 and SRB-38 
nanobodies (2 µg/ml) and negative control nanobody were added 
and their binding to CD19 was detected by horseradish peroxidase 
(HRP)-labeled anti-HA antibody. Each point represents the average 
of three repetitions±SD
 
  
Figure 7. Competitive ELISA: The experiments to determine ability 
of soluble CD19 antigen to inhibit binding of selected anti-CD19 
nanobodies (SRB-37 and SRB-85) and negative control to the coated 
antigen. Data represents the mean of three repetitions±SD
kDa (nM) CD19 Nanobody 33 SRB-37 15 SRB-85 
 
Table 3. Affinity of anti-CD19 nanobodies  
  Figure 8. Immunoreactivity of nominated nanobodies toward 
Namalwa- expressing CD19 cells. The mixture of the two selected 
nanobodies showed a high signal (Kruskal–Wallis one-way analysis of variance, P=0.003). The graph represents a summary of the results of three independent assays
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them have some limiting features such as big size, HAMA 
generation, and unstable protein structure, which are 
destroyed following pH and temperature changes. As far 
as we know, this is the first study, describing anti-CD19 
Nbs (VHHs). Since the discovery of camelid heavy-chain antibodies about 20 to 25 years ago, their single-domain 
antigen-binding fragments also called VHHs or Nbs, 
have received a progressively increasing interest (12). 
Having many beneficial properties, Nbs as stable and 
firm recombinant entities are highly valued proteins for multiple applications, including fundamental research, 
diagnosis, and therapeutic purposes (38). Due to the 
distinct Nb-based applications, they are currently 
undergoing extensive research and  development in 
many applied as therapeutics against extracellular 
receptors as target( EGFR, HER2, c-MET, VEGFR, DR5, 
and CXCR4/7), ligands as target (HGF, VEGF, uPA, 
and CXCL11/12), drug delivery moieties as targets 
(VEGFR2, EGFR, c-MET, HER2, and MUC1), a particles 
to deliver (liposomes, micelles, NANAPs, polymersomes, 
polyplexes, and intrabodies), diagnostic tools such as 
extracellular receptors (AFP, CAIX, PMSA, TAG-72, and 
HER2) and  imaging targets such as PMSA, MMR, HER2, 
HGF, VCAM1, CAIX, and EGFR (39, 40). Phage-display antibody technology has become increasingly popular for manufacturing binding sites and application in all 
fields of medical and industrial researches (37). The 
VHH selected from immunized camels or llamas has 
possessed some advantages in comparison with the Fab 
and scFv. VHH technology directly excludes a number of 
non-specific clones and it is a straightforward method 
for achieving the target clones (41). As a result of the precise application of camel immunization by B-cells, 
we could create a very rich library, which is very useful to search for B-cell surface receptors, especially 
CD19, CD20 and CD21 for targeting B-cell malignancy 
(such as non-Hodgkin lymphoma), as well as for B-cell 
autoimmunity (such as systemic lupus erythematosus) 
(42).B-cell depletion therapy, administrating mAbs alone 
or in combination with chemotherapeutic drugs and 
radiotherapy has exceedingly developed to treat various hematological malignancies and to prolong overall 
patient survival (43). A promising antibody among the 
many well-responded mAbs is anti-CD20 (RTX) (42). 
Anti-CD20 mAbs, particularly RTX have been identified 
as being deficient due to inducing resistance in patients; 
therefore, a need for alternative strategies is felt (6). 
Anti- CD19, another B cell-specific cell surface antigen, can be utilized as a potential complementary to anti-B 
cell mAbs. CD19 is a B- cell surface receptor whose vast 
expression, from pre-B cell to early plasma cell, makes 
it a significant feature for immunotherapy and targeted 
drug delivery in B-cell malignancies (44). Internalization of this receptor is also favorable for targeted drug 
delivery. In the present study, we demonstrated that 
anti-CD19 Nb can effectively target malignant cell lines 
in vitro, which resulted in the introduction of two novel 
anti-CD19 Nbs, with a small size and high efficacy (45).A main factor regulating successful tumor targeting by 
 
  
Figure 9. Anti CD19 nanobody specifically binds to antigen-positive cells; (A) Raji cell line with nanobody (SRB-37,85) plus anti-His-FITC (B) Raji 
anti CD19-PE positive control, (C) Ramos cell line with nanobody (SRB-37,85) plus anti-His-FITC (D) Ramos anti-CD19-PE positive control (E) 
Namalwa cell line with nanobody (SRB-37,85) plus anti-His-FITC (F) Namalwa anti-CD19-PE positive control (G) Daudi cell line with nanobody 
(SRB-37,85) plus anti-His -FITC (H) Daudi anti-CD19-PE positive control (I) K562 cell line with nanobody (SRB-37,85) plus anti-His-FITC (J) guide 
figure line
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antibodies is their binding affinity for the target antigen 
(46), which can determine fundamental properties of 
mAbs such as cell penetration, localization, specificity, 
and efficacy (47). In order to achieve high affinity clones, 
we used very low concentration of the antigen. We 
managed to isolate a panel of CD19-specific Nbs after 
the last round of selection, with the affinity of isolated 
Nbs, estimated at the standard range of 15-35 nM. 
Considering the flow cytometry results, the normal 
expression of CD19 on the B-cell is very different (48).
Our results showed that the cocktail Nb binds to 
Ramos more than Daudi, Raji and Namalwa cell lines 
and dose not target the negative control cell line (K562). It should be noted that Ramos cells compared to other 
cell lines expressed higher levels of CD19 antigen. 
Target specificity of Nbs without causing any damage 
to the normal cell is a basic and essential requirement 
for stringent targeting of the tumors. One of the main 
achievements of this research was monitoring and 
repressing a highly specific CD19 receptor by delivering 
a toxin to tumor B-cells, which will be covered in our future articles. 
A major challenge associated with applying murine 
anti-CD19 and CD20 antibodies is the stimulation of the host immune response such as HAMA generation 
in a few individuals among the patients (48). Our 
sequencing results implied high sequence homology 
(approximately 90%) between the Nb and Homa 
variable immunoglobulin domains (37). Thus, it may be 
predicted that potentially low immunogenicity may be 
induced in human subjects. Another advantage of the Nb 
that makes it distinguishable from other conventional 
antibodies is the antigen binding loops (15). The 
antigen-binding site of Nbs show a much greater structural repertoire that is observed in conventional 
VH (49). More importantly, the CDR3 regions of Nbs are 
on average longer than those observed in VH(49, 50). 
The length of VH amino acids is about 9-12 amino acids, 
whereas in dromedary derived Nbs, a length of 16-18 amino acids is typically detected. According to our 
findings, extracted CDR3 region of SRB-37 and SRB-85 
Nbs consisted of 9 and 19 amino acids, respectively.
The other advantage of Nbs is their high solubility and stability due to amino acid replacement. Replacing 
hydrophobic amino acids with their hydrophilic 
counterparts (V37F or V37Y, G44E, L45R and W47G) 
within the FR2 region (the residues in this region of the 
VH are usually connected to the VL domain and are well-
conserved through evolution) is a potential solution as 
demonstrated in our Nbs (Table 2)(49, 50).
Conclusion
This is the first report on the production of nanobody 
against human CD19. Following in vivo analysis, the 
produced Nbs have the potential to be used as research and diagnostic tools, small molecule drugs and in drug delivery systems against B-cell malignancy and autoimmune disease. 
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